¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Solicitud de permisos - Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

FI 2016

© Thomson Reuters, Journal Citation Reports, 2016

Indexada en:

SCIE/Journal of Citation Reports, Index Medicus/Medline, Excerpta Medica/EMBASE, SCOPUS, CANCERLIT, IBECS


  • Factor de Impacto: 0,917 (2016)
  • SCImago Journal Rank (SJR):0,246
  • Source Normalized Impact per Paper (SNIP):0,264

© Thomson Reuters, Journal Citation Reports, 2016

Gastroenterol Hepatol 2003;26:166-8 - DOI: 10.1016/S0210-5705(03)79068-2
Nuevas perspectivas terapéuticas en el esófago de Barrett
A. Lanas
Sección de Gastroenterología Oncológica. Hospital Clínico Universitario de Zaragoza. España
El Texto completo solo está disponible en PDF
S.J. Spechler
Barrett's esophagus
N Engl J Med, 346 (2002), pp. 836-842 http://dx.doi.org/10.1056/NEJMcp012118
J. Lagergren,R. Bergström,A. Lindgren,O. Nyrén
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
N Engl J Med, 340 (1999), pp. 825-831 http://dx.doi.org/10.1056/NEJM199903183401101
W.K. Hirota,T.M. Loughney,D.J. Lazas,C.L. Maydonovitch,V. Rholl
Wong RKH. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data
Gastroenterology, 116 (1999), pp. 277-285
J. Alcedo,A. Lanas,A. Ferrández,F. Sopeña,J. Arenas
Trends in the epidemiology and outcome of Barrett's esophagus in Spain
Gut, 51 (2002), pp. 27
C. Morales,R.F. Souza,S.J. Spechler
Hallmarks of cancer progression in Barrett's oesophagus
V.N. Shirvani,R. Ouatu-Lascar,B.S. Kaur,B. Omary,G. Triadafilopoulos
Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure
Gastroenterology, 118 (2000), pp. 487-496
A.P. Weston,S.K. Banerjee,P. Sharma,T.M. Tran,R. Richards,R. Cherian
p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression
Am J Gastroenterol, 96 (2001), pp. 1355-1362 http://dx.doi.org/10.1111/j.1572-0241.2001.03851.x
B.J. Reid,D.S. Levine,G. Longton,P.L. Blount,P.S. Rabinovitch
Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low-and highrisk patient subsets
Am J Gastroenterol, 95 (2000), pp. 1669-1676 http://dx.doi.org/10.1111/j.1572-0241.2000.02196.x
R.E. Sampliner
Updated guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus
Am J Gastroenterol, 97 (2002), pp. 1888-1895 http://dx.doi.org/10.1111/j.1572-0241.2002.05910.x
W. Ye,W.H. Chow,J. Lagergren,L. Yin,O. Nyren
Risk of adenocarcinoma of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery
Gastroenterology, 121 (2001), pp. 1286-1293
J.A. Jankowski,D. Provenzale,P. Moayyedi
Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west
Gastroenterology, 122 (2002), pp. 588-590
P. Sharma
An update on strategies for eradication of Barrett's mucosa
Am J Med, 111 (2001), pp. 147-152
J. Van den Boogert,R. Van Hillegersberg,P.D. Siersema,R.W.F. De Bruin,H.W. Tilanus
Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review
Am J Gastroenterol, 94 (1999), pp. 1153-1160 http://dx.doi.org/10.1111/j.1572-0241.1999.01058.x
B.F. Overholt,M. Panjehpour,J.M. Haydek
Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients
Gastrointest Endosc, 49 (1999), pp. 1-7
R.J. Pacifico,K.K. Wang
Role of mucosal ablative therapy in the treatment of the columnar-lined esophagus
Chest Surg Clin N Am, 12 (2002), pp. 185-203
M.J. Langman,K.K. Cheng,E.A. Gilman,R.J. Lancashire
Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database
Br Med J, 320 (2000), pp. 1642-1646
G.P. Morgan,J.G. Williams
Tumouricidal effect of indomethacin in the esophagus
Postgrad Med J, 69 (1993), pp. 960
N.S. Buttar,K.K. Wang,M.A. Anderson,R.A. Dierkhising,R.J. Pacifico,K.K. Krishnadath
The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epitelium: an in vitro study
J Natl Cancer Inst, 94 (2002), pp. 422-429
N.S. Buttar,K.K. Wang,O. Leontovich,J.Y. Westcott,R.J. Pacifico,M.A. Anderson
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitores in an animal model of Barrett's esophagus
Gastroenterology, 122 (2002), pp. 1101-1112
B.S. Kaur,N. Khamnehei,M. Iravani,S.S. Namburu,O. Lin,G. Triadafilopoulos
Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus
Gastroenterology, 123 (2002), pp. 60-67
A. Lanas,F. Soteras,P. Jiménez,I. Fiteni,E. Piazuelo,Y. Royo,J. Ortego
Superoxide anion and nitric oxide in high-grade esophagitis induced by acid and pepsin in rabbits
Dig Dis Sci, 46 (2001), pp. 2733-2743
H. Akgun,J. Lechago,M. Younes
Estrogen receptor-beta is expressed in Barrett's metaplasia and associated adenocarcinoma of the esophagus
Anticancer Res, 22 (2002), pp. 1459-1461
Copyright © 2003. Elsevier España, S.L.